Alpha -Tocopherol Ascorbic Acid Biotin Calcium Car

證據等級: L5

預測適應症: 0 個

Multi-Vitamin/Mineral + Omega-3 Complex: Insufficient Data for Repurposing Analysis

One-Sentence Summary

This candidate is a 13-component nutritional supplement combining vitamins, minerals, and omega-3 fatty acids (DHA/EPA), with no current market authorization in Taiwan and no defined approved indication. The TxGNN model returned no predicted indications for this submission, as multi-component combinations cannot be mapped to a single DrugBank identifier required for graph-based prediction. Without model output or an established original indication, a standard repurposing evaluation cannot be completed at this stage.

Quick Overview

Item	Content
Original Indication	Not established — no Taiwan approval records found
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction unavailable; no supporting studies identified)
Taiwan Market Status	✗ Not Marketed
Number of Licenses	0
Recommended Decision	Hold

Why No Prediction Was Generated

This submission contains 13 distinct active pharmaceutical ingredients spanning three pharmacological categories:

Vitamins

Alpha-Tocopherol (Vitamin E)
Ascorbic Acid (Vitamin C)
Biotin (Vitamin B7)
Cholecalciferol (Vitamin D3)
Cyanocobalamin (Vitamin B12)
Folic Acid (Vitamin B9)
Pyridoxine (Vitamin B6)

Minerals

Calcium Carbonate
Ferrous Fumarate (Iron)
Magnesium Oxide
Potassium Iodide

Omega-3 Fatty Acids

Doconexent (DHA — Docosahexaenoic acid)
Icosapent (EPA — Eicosapentaenoic acid)

The TxGNN model operates on single-entity DrugBank identifiers. A fixed-dose combination product containing 13 ingredients cannot be assigned a unified DrugBank ID, which prevents the model from constructing a knowledge graph embedding and generating repurposing candidates. This is a known structural limitation of graph-based repurposing pipelines when applied to multi-ingredient formulas.

Based on the ingredient profile — particularly Folic Acid, DHA, Iron, Iodine, and Vitamin D3 — this combination is highly consistent with a prenatal or perinatal nutritional supplement. However, no approved indication is on record for this specific formulation in Taiwan, and no international regulatory reference was identified during the query window.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline cannot process multi-component combinations without a unified DrugBank ID, and no approved indication or safety documentation is available to support a repurposing baseline assessment.

To proceed, the following is needed:

Clarify intended use: Confirm whether this combination is intended as a prenatal supplement, general multivitamin, or a condition-specific nutritional therapy, to provide clinical context for subsequent evaluation
Decompose and run individual predictions: Submit key pharmacologically active components separately — particularly Doconexent (DHA), Icosapent (EPA), and Folic Acid — which each hold individual DrugBank IDs and can be processed by TxGNN independently
Identify international authorizations: Search FDA (US), EMA, or other major regulators for approved products with a similar composition to establish indication reference and safety baseline
Obtain package insert: Retrieve product labeling from TFDA or an equivalent authority to complete the safety gap (DG001) and establish contraindications and warnings
Resolve DrugBank mapping (DG002): Since drugbank_id is null, conduct a manual or API-assisted mapping for each individual ingredient to enable mechanism-of-action analysis
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.